Crucell's mission is to develop, produce and market vaccines and antibodies that prevent or treat infectious diseases.
€213.1m - Total revenue and other operating income in 200734% - Gross margin in 2007€22.2m - Operating net cash flow in 2007

Message from our CEO

Ronald H.P. Brus

Ronald H.P. Brus
President and
Chief Executive Officer

Crucell is a rapidly growing biopharmaceutical company with ambitious goals. We aim to create shareholder value by following a clear and convincing strategy for growth.

Read full statement

2007 - 163.2, 2006 - 157.8, 2005 - 111.7, 2004 - 76.7

Downloads

Crucell Annual Report and Form 20–F – (PDF – 5.3MB)

To view a PDF file, you will need to download Adobe Acrobat Reader from Adobe.com.